Phase 1/1b study of AB928 in combination with AB122 or chemotherapy in patients with Non-small cell lung cancer and renal cell carcinoma
Phase of Trial: Phase I
Latest Information Update: 11 Jun 2018
Price : $35 *
At a glance
- Drugs AB 122 (Primary) ; AB-928 (Primary)
- Indications Non-small cell lung cancer; Renal cancer
- Focus Adverse reactions
- 11 Jun 2018 According to the Arcus Biosciences media release, the IND application for this trial will be submitted this month.
- 16 May 2018 New trial record
- 09 May 2018 According to the Arcus Biosciences media release, company initiated the submission of regulatory filings for this trial and data from the dose-escalation portion of this trial will be presented in the first half of 2019.